Paras Biopharmaceuticals Finland

Paras Biopharmaceuticals is a private, pre-revenue Finnish biotech focused on developing biosimilars and proprietary microbial expression technologies. The company operates a three-pronged business model encompassing a microbial biologics CDMO service, biosimilar technology development partnerships, and the sale of recombinant bioprocess enzymes. With a suite of proprietary platforms like Diabrid®, NobleCleav®, and Biomultifold®, Paras aims to enable cost-effective, high-yield production of complex therapeutic proteins and peptides. It is actively seeking partners to advance its pipeline of biosimilar candidates for osteoporosis, rheumatoid arthritis, and other conditions.

Proprietary microbial expression and protein processing platform including Diabrid® (high-level expression), NobleCleav® (fusion protein cleavage), Biomultifold® (high-yield E. coli process), and Cytofold StructQuant® (cytoplasmic protein folding) technologies.

Paras competes with large, global CDMOs and numerous biosimilar developers. Its differentiation relies on demonstrating superior yield and cost-effectiveness for complex peptides and proteins in microbial systems, a niche but competitive segment of the biologics market.